Executive Director
Bristol-Myers Squibb Company
Dr. Vibha Jawa is an Executive Director in Clinical-Pharmacology/Pharmacometrics and Bioanalysis organization at Bristol Myers Squibb. She leads biotherapeutic and cell /gene therapy bioanalytical (BA), DMPK and immunogenicity, and provides strategic and scientific oversight for BMS developmental portfolio. She has lead the Predictive/Clinical Immunogenicity at Merck( 4yrs) and Discovery to Development for biotherapeutics at Amgen(14yrs). Her 20+ years of experience in diverse fields of biologics , vaccine development and gene therapy has led to successful support of 20 + IND, BLA and MAA filings. She has 75+ peer-reviewed publications and serves as a Reviewer and section Editor for The AAPS Journal, Frontiers Immunol and J. Pharm Sci as well as active member of multiple scientific societies and consortiums ( IQ, SC space Consortium and EIP) . Within AAPS, she is Track Chair of Summer Scientific Forum Meeting, Chair of the CGTP Bioanalysis/Biomarker working group , SCmember of the TPI Community, past chair of Immunogenicity Risk Assessment and Mitigation Community and leads the IQ Consortium for Cell/Viral/Gene therapies. She was recognized as the AAPS Fellow 2022. Vibha enjoys volunteering as a board member for the state youth orchestra and mentoring high school students on STEM related projects in her free time.